Investors
People are different and so is their cancer, patients should be treated individually.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Read
Latest News
Extended Partnership with Werfen strengthens 2cureX’s Iberian distribution network
Read more
Please click here to download our Articles of association
2cureX presents at Redeye Investor AW in Malmø, Sweden
Redeye events list
2cureX presents at Redeye Medtech event in Stockholm, Sweden
Interim Report Q3 2022 released
View previous reports
Q3 Report webcast and Q&A session
IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.
